Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma
Year: 2026
Type: article
Abstract: OBJECTIVE: To investigate the short-term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima-type palmoplantar keratoderma (NPPK). METHODS: A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12. RESULTS: The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction). CONCLUSIONS: Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long-term efficacy and safety.
DOI: 10.1111/ddg.70543
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G200882490, G3316130868
OpenAlex ID: W7233858474
